Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Crizotinib was associated with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases, however, progression of preexisting or development of new intrac Cranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotin ib.